Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04504604 · ClinicalTrials.gov registry record · NA
TCF-001 TRACK (Target Rare Cancer Knowledge) Study
A NA study of Cholangiocarcinoma and Rare Cancers, sponsored by TargetCancer Foundation.
- Recruiting
- Registry status
- NA
- Development phase
- 400
- Enrollment target
- 1
- Study location
NCT04504604 is a NA study of Cholangiocarcinoma and Rare Cancers that is actively recruiting participants, run by TargetCancer Foundation. The registered enrollment target is 400 participants, roughly in line with the 379-participant average among 60 other Cholangiocarcinoma trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT04504604, a NA study of Cholangiocarcinoma and Rare Cancers, is actively recruiting participants, sponsored by TargetCancer Foundation.
- RECRUITING
- Registry status
- NA
- Development phase
- 400 participants
- Enrollment target
- 1
- Study location
Study Summary
This open label, non-randomized, multi-center, pragmatic study aims to establish whether patients with rare tumors can benefit from matched molecular therapy as dictated by their next-generation sequencing (NGS) results.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST FoundationOne CDx and FoundationOne Liquid CDx
Study Locations (1)
Massachusetts
- TargetCancer Foundation - Cambridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2020-10-01 |
| Est. Completion | 2025-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04504604
The ClinicalTrials.gov registry entry for NCT04504604 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 379-participant average among 60 other Cholangiocarcinoma trials with a reported enrollment target. The listed sponsor is TargetCancer Foundation, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Cholangiocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which FoundationOne CDx and FoundationOne Liquid CDx is the first listed.
NCT04504604 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04504604 about?
NCT04504604 is a clinical study titled "TCF-001 TRACK (Target Rare Cancer Knowledge) Study". This open label, non-randomized, multi-center, pragmatic study aims to establish whether patients with rare tumors can benefit from matched molecular therapy as dictated by their next-generation sequencing (NGS) results.
What is the current status of trial NCT04504604?
This trial is currently recruiting. It is a NA study. The enrollment target is 400 participants. The study started on 2020-10-01. Estimated completion is 2025-12.
What conditions does trial NCT04504604 study?
This clinical trial studies the following conditions: Cholangiocarcinoma, Rare Cancers, Cancer of Unknown Primary Site.
What interventions are being tested in trial NCT04504604?
The interventions under investigation include: FoundationOne CDx and FoundationOne Liquid CDx (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04504604?
This trial is sponsored by TargetCancer Foundation, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04504604 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cholangiocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Targeted Navigation in Hepatocellular Carcinoma (HCC)
RECRUITING · NA
-
The Dragon PLC Trial (DRAGON-PLC)
RECRUITING · NA
-
HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer
RECRUITING · NA
-
High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery
RECRUITING · NA
-
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
RECRUITING · NA
-
Implementing a Randomized Control Trial to Test the Expanded Web-based Decision Aid
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.